S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:SEEL

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

$0.18
+0.01 (+5.75%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.17
$0.20
50-Day Range
$0.16
$1.58
52-Week Range
$0.15
$1.66
Volume
5.46 million shs
Average Volume
9.62 million shs
Market Capitalization
$23.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.33

Seelos Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
1,168.1% Upside
$2.33 Price Target
Short Interest
Healthy
4.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Seelos Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.43) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

766th out of 970 stocks

Pharmaceutical Preparations Industry

364th out of 450 stocks


SEEL stock logo

About Seelos Therapeutics (NASDAQ:SEEL) Stock

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

SEEL Price History

SEEL Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Where Seelos Therapeutics Stands With Analysts
Why Is Seelos Therapeutics (SEEL) Stock Down 25% Today?
4 Analysts Have This to Say About Seelos Therapeutics
See More Headlines
Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SEEL Company Calendar

Today
9/30/2023
Next Earnings (Estimated)
10/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SEEL
Employees
16
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$2.33
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+1,168.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-73,530,000.00
Pretax Margin
-7,096.85%
Return on Equity
-10,287.49%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.10) per share

Miscellaneous

Free Float
119,706,000
Market Cap
$23.53 million
Optionable
Not Optionable
Beta
1.90

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Raj Mehra J.D. (Age 63)
    Ph.D., Founder, Chairman, CEO & Pres
    Comp: $854.73k
  • Mr. Michael J. Golembiewski (Age 51)
    Chief Financial Officer
    Comp: $454.83k
  • Ms. Kimberly Farrand
    Sr. Director of Clinical Devel. & Operations
  • Mr. Anthony Marciano
    Chief Communications Officer
  • Gopal Krishna Ph.D.
    Head of Manufacturing & Technical Operations
  • Tim Whitaker M.D.
    Chief Medical Officer
  • Ms. Karen Fusaro
    Sr. VP & Head of Clinical Operations













SEEL Stock - Frequently Asked Questions

Should I buy or sell Seelos Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SEEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEEL, but not buy additional shares or sell existing shares.
View SEEL analyst ratings
or view top-rated stocks.

What is Seelos Therapeutics' stock price forecast for 2023?

3 brokers have issued twelve-month price objectives for Seelos Therapeutics' stock. Their SEEL share price forecasts range from $1.00 to $4.00. On average, they expect the company's stock price to reach $2.33 in the next twelve months. This suggests a possible upside of 1,168.1% from the stock's current price.
View analysts price targets for SEEL
or view top-rated stocks among Wall Street analysts.

How have SEEL shares performed in 2023?

Seelos Therapeutics' stock was trading at $0.6790 at the beginning of 2023. Since then, SEEL stock has decreased by 72.9% and is now trading at $0.1840.
View the best growth stocks for 2023 here
.

When is Seelos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 6th 2023.
View our SEEL earnings forecast
.

What ETF holds Seelos Therapeutics' stock ?

AdvisorShares Psychedelics ETF holds 312,582 shares of SEEL stock, representing 5.70% of its portfolio.

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

How do I buy shares of Seelos Therapeutics?

Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $0.18.

How much money does Seelos Therapeutics make?

Seelos Therapeutics (NASDAQ:SEEL) has a market capitalization of $23.53 million.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.seelostherapeutics.com. The company can be reached via phone at (646) 293-2100, via email at anthony.marciano@seelostx.com, or via fax at 858-436-8155.

This page (NASDAQ:SEEL) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -